Since its inception more than 100 years ago, Clorox has expanded to operate in an array of consumer product categories, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water filtration products, and natural personal-care products... Show more
The Clorox Company (CLX) operates as a consumer packaged goods (CPG) leader with a portfolio spanning cleaning, health and wellness, household, lifestyle, and international segments. Roughly 80% of its sales are generated in the United States, where brands such as Clorox, Glad, Hidden Valley, Fresh Step, Brita, Burt's Bees, and now Purell hold category-leading positions. This brand breadth provides durable pricing power and retail shelf presence, but it also ties the company closely to slower-growing, mature categories where private-label competition is intensifying.
Strategically, Clorox is in the midst of a multi-year transformation. Its five-year digital overhaul, anchored by a new ERP system, was completed in fiscal 2026, with management signaling that the emphasis now shifts from implementation to harvesting efficiency gains across supply chain, logistics, and selling costs. The acquisition of GOJO Industries, completed in April 2026, expands Clorox's footprint in health and hygiene—a structurally attractive adjacency—while adding an approximately $800 million business growing in the mid-single digits. Medium-term positioning therefore hinges on whether Clorox can convert these investments into steadier, more predictable organic growth and margin expansion.
Several developments could influence investor sentiment over the coming quarters. First, the GOJO (Purell) integration is the defining catalyst: management targets roughly $50 million in run-rate cost synergies over time, but the deal is expected to be earnings-neutral in year one and carries execution risk. Progress on synergy realization and revenue momentum will be closely watched.
Second, the CEO transition introduces uncertainty. With a leadership search still underway as of the most recent disclosures, the incoming executive's approach to reinvestment, capital allocation, and the company's 48-year streak of dividend increases represents a potential strategic inflection point.
Third, margin trajectory is a focal point. Management has guided for gross-margin recovery to begin in the back half of fiscal 2027 as productivity savings offset roughly $200 million-plus of commodity inflation. Fourth, brand-specific turnarounds—notably the multi-year reinvention of Fresh Step cat litter and share recovery in the Food segment—will test execution. On the analyst front, recent revisions have been mixed: firms including Morgan Stanley and UBS have nudged targets higher, while others such as Goldman Sachs and J.P. Morgan maintain more cautious (Sell-equivalent) stances, contributing to a consensus "Hold" rating and an average price target near $97.75.
Clorox's trajectory is closely tied to the broader consumer staples environment. Persistent inflation, particularly in resin and other petroleum-linked inputs, has compressed margins, with management modeling roughly $100-per-barrel oil at the time of its latest guidance. Higher interest rates also matter indirectly, raising financing costs tied to the GOJO acquisition and increasing the hurdle for capital allocation decisions.
On the demand side, consumers remain value-focused, favoring promotions and in some categories trading toward lower-priced alternatives. This dynamic has kept competitive and promotional intensity elevated across cleaning and food categories. Geopolitical factors, including tariff policy and currency movements, add further sensitivity to an international segment that has nonetheless delivered resilient growth. Finally, a structural theme worth monitoring is the impact of GLP-1 (glucagon-like peptide-1) weight-loss medications on food consumption patterns, which management has flagged as a consumer trend to watch in the Food category.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help traders assess whether a stock, ETF, or other asset may move bullish, bearish, or sideways over the next week or month. It is built to assist users in spotting developing trends, evaluating possible breakouts or reversals, and exploring predictions across a wide range of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. For investors following CLX and similar names, the Trend Prediction Engine offers a data-driven complement to fundamental research and analyst commentary.
Looking toward the remainder of fiscal 2027 and beyond, Clorox's guidance frames a transition year: net sales growth of roughly 13% to 14% is largely acquisition-driven, while adjusted EPS (earnings per share) of $5.70 to $6.00 is expected to trend toward the lower end amid elevated input-cost inflation. The long-term story will depend on three structural themes.
Cost-structure evolution: With the ERP rollout complete, Clorox is shifting toward a productivity-led earnings phase. If the promised savings materialize, margins could rebuild meaningfully from depressed levels, but the timing and magnitude remain key uncertainties.
Health and hygiene expansion: The GOJO acquisition positions Clorox to grow beyond mature household categories into a more resilient health-and-wellness adjacency, provided integration and cross-selling execute smoothly.
Competitive and regulatory landscape: Private-label encroachment, retailer concentration, and potential tariff or regulatory shifts all pose structural risks that could cap organic growth. Meanwhile, capital allocation priorities—dividend continuity, share repurchases, and debt reduction following a leveraged acquisition—will shape shareholder returns. Consensus expectations currently embed modest, acquisition-aided growth rather than a rapid re-rating, keeping the forward view balanced between recovery potential and execution risk.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AGG | 96.15 | 0.59 | +0.62% |
| iShares Core U.S. Aggregate Bond ETF (AGG) | |||
| FPRO | 25.01 | N/A | N/A |
| Fidelity Real Estate Investment ETF (FPRO) | |||
| MYN | 8.72 | -0.08 | -0.91% |
| Blackrock Muniyield NEW York Quality Fund | |||
| EFAD | 44.21 | -0.73 | -1.63% |
| ProShares MSCI EAFE Dividend Growers ETF (EFAD) | |||
| QVMS | 31.07 | -0.71 | -2.24% |
| Invesco S&P SmallCap 600 QVM Multi-factor ETF (QVMS) | |||
A.I.dvisor indicates that over the last year, CLX has been loosely correlated with PG. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CLX jumps, then PG could also see price increases.
a maker of detergent and cleaning products
Industry HouseholdPersonalCare
The 10-day moving average for CLX crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 62%.
CLX moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLX advanced for three days, in 181 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
The Aroon Indicator entered an Uptrend today. In 75 of 193 cases where CLX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 39%.
The 10-day RSI Indicator for CLX moved out of overbought territory on November 19, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 12 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 55%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 30 of 55 cases where CLX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 55%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
CLX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron SMR rating for this company is 10 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. CLX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CLX's P/B Ratio (134.314) is slightly higher than the industry average of (21.731). P/E Ratio (20.739) is within average values for comparable stocks, (16.288). Projected Growth (PEG Ratio) (1.019) is also within normal values, averaging (1.518). Dividend Yield (0.050) settles around the average of (0.032) among similar stocks. P/S Ratio (1.542) is also within normal values, averaging (1.902).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.